Keytruda + chemo improved OS in HER2-negative gastric or GEJ cancer regardless of PD-L1 expression

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Results from the pivotal phase III KEYNOTE-859 trial showed that Keytruda (pembrolizumab) plus chemotherapy significantly improved overall survival for patients with human epidermal growth factor receptor 2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login